Proteinuria among patients with chronic kidney disease: A performance measure for improving patient outcomes

Joint Commission Journal on Quality and Patient Safety

Volumn 38, Issue 6, 2012, Pages 277-282

  Thorp, Micah L ^a   Smith, David H ^a   Johnson, Eric S ^a   Vupputuri, Suma ^a   Weiss, Jessica W ^b   Petrik, Amanda F ^a   Yang, Xuihai ^a   Levey, Andrew S ^c   Wasse, Haimanot ^d   Muoneke, Rosemary ^a   Snyder, Susan R ^e,f  

^a KAISER PERMANENTE   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c TUFTS MEDICAL CENTER   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^f BATTELLE MEMORIAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHRONIC KIDNEY FAILURE; HEALTH CARE QUALITY; HUMAN; ORGANIZATION AND MANAGEMENT; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PROTEINURIA; REVIEW; TOTAL QUALITY MANAGEMENT; TREATMENT OUTCOME;

HUMANS; KIDNEY FAILURE, CHRONIC; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); PRACTICE GUIDELINES AS TOPIC; PROTEINURIA; QUALITY IMPROVEMENT; QUALITY INDICATORS, HEALTH CARE;

EID: 84862192599     PISSN: 15537250     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1553-7250(12)38035-5     Document Type: Article

References (37)

1. US Renal Data System. 2005 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2005.
2. Coresh J, et al. Prevalence of high blood pressure and elevated serum creatinine level in the United States: Findings from the third National Health and Nutrition Examination Survey (1988-1994). Arch Intern Med. 2001 May 14;161(9):1207-1216.
3. Hunsicker LG, et al. Predictors of the progression of renal disease in the Modification of Diet in Renal Disease Study. Kidney Int. 1997; 51(6):1908-1919. (Pubitemid 27252762)
4. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis. 1998 Nov;32(5 Suppl 3):S112-119. (Pubitemid 28527268)
5. K/DOQI. K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Am J Kidney Dis. 2002 Feb;39(Suppl 1):S1-266.
6. Landon BE, et al. Physician clinical performance assessment: Prospects and barriers. JAMA. 2003 Sep 3;290(9):1183-1189. (Pubitemid 37430424)
7. US Preventive Services Task Force. Methods and Processes. Jan 2011. Accessed May 1, 2012. http://ahrq.gov/clinic/uspstmeth.htm.
8. Harris RP, et al. Current methods of the U.S. Preventive Services Task Force: A review of the process. Am J Prev Med. 2001;20(3 Suppl):21-35. (Pubitemid 33732964)
9. Norris SL, et al. Screening adults for type 2 diabetes: A review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2008 Jun 3;148(11):855-868. (Pubitemid 351786934)
10. National Collaborating Centre for Chronic Conditions. Chronic Kidney Disease: National Clinical Guideline for Early Identification and Management in Adults in Primary and Secondary Care. London: Royal College of Physicians, 2008.
11. Methven S, et al. Assessing proteinuria in chronic kidney disease: Proteincreatinine ratio versus albumin-creatinine ratio. Nephrol Dial Transplant. Epub 2010 Mar 17.
12. Coresh J, et al. Prevalence of chronic kidney disease in the United States. JAMA. 2007 Nov 7; 298(17):2038-2047. (Pubitemid 350074801)
13. Eborall HC, et al. Psychological impact of screening for type 2 diabetes: Controlled trial and comparative study embedded in the ADDITION (Cambridge) randomised controlled trial. BMJ. 2007 Sep 8;335(7618):486.
14. Sheridan S, Pignone M, Donahue K. Screening for high blood pressure: A review of the evidence for the U.S. Preventive Services Task Force. Am J Prev Med. 2003;25(2):151-158. (Pubitemid 36918355)
15. Stolk RP. Screening for diabetes. BMJ. 2007 Sep 8;335(7618):457-458. (Pubitemid 47401591)
16. Kent DM, et al. Progression risk, urinary protein excretion, and treatment effects of angiotensin-converting enzyme inhibitors in nondiabetic kidney disease. J Am Soc Nephrol. 2007;18(6):1959-1965.
17. Ruggenenti P, et al. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet. 1999 Jul 31;354(9176):359-364. (Pubitemid 29355751)
18. Strippoli GFM, et al. Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease. Cochrane Database Syst Rev. 2006 Oct 18;(4):CD006257.
19. Wright JT Jr, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: Results from the AASK trial. JAMA. 2002 Nov 20;288(19):2421-2431. (Pubitemid 35340538)
20. Singh NP, et al. Angiotensin converting enzyme inhibitors and cough-A north Indian study. J Assoc Physicians India. 1998;46(5):448-451. (Pubitemid 128523774)
21. Ng WY, Lui KF, Thai AC. Evaluation of a rapid screening test for microalbuminuria with a spot measurement of urine albumin-creatinine ratio. Ann Acad Med Singapore. 2000;29(1):62-65.
22. Rodby RA, et al. The urine protein to creatinine ratio as a predictor of 24- hour urine protein excretion in type 1 diabetic patients with nephropathy. The Collaborative Study Group. Am J Kidney Dis. 1995;26(6):904-909.
23. Schwab SJ, Dunn FL, Feinglos MN. Screening for microalbuminuria: A comparison of single sample methods of collection and techniques of albumin analysis. Diabetes Care. 1992;15(11):1581-1584.
24. National Institute for Health and Clinical Excellence, National Collaborating Center for Chronic Conditions. Chronic Kidney Disease: National Clinical Guideline for Early Identification and Management in Adults in Primary and Secondary Care. London: United Kingdom, Royal College of Physicians, 2010.
25. American Diabetes Association. Standards of medical care in diabetes- 2010. Diabetes Care. 2010(1):33 Suppl 1:S11-61.
26. Kidney Disease Outcomes Quality Initiative (K/DOQI). K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis. 2004;43(5 Suppl 1):S1-290.
27. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Bethesda, MD: National Heart, Lung, and Blood Institute, 2004.
28. Brenner BM, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001 Sep 20;345(12):861-869.
29. Parving HH, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001 Sep 20;345(12):870-878.
30. American Diabetes Association. Standards of Medical Care in Diabetes- 2011. Diabetes Care. Jan 2011. Accessed Apr 25, 2012. http://care.diabetes journals.org/content/34/Supplement-1/S11.full.pdf
31. National Committee for Quality Assurance. HEDIS 2009 Volume 2 Technical Update. Oct 1, 2008. Accessed Apr 25, 2012. http://www.ncqa.org/Portals/0/ PolicyUpdates/HEDIS%20Technical%20Updates/09-CDC-Spec.pdf.
32. Hou FF, et al. Efficacy and safety of benazepril for advanced chronic renal insufficiency. N Engl J Med. 2006 Jan 12;354(2):131-140.
33. Lewis EJ, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001 Sep 20;345(12):851-860.
34. Kamper AL, Strandgaard S, Leyssac PP. Effect of enalapril on the progression of chronic renal failure. A randomized controlled trial. Am J Hypertens. 1992 Jul;5(7):423-430.
35. Maschio G, et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin- Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med. 1996 Apr 11;334(15):939-945. (Pubitemid 26114159)
36. Ihle BU, et al. Angiotensin-converting enzyme inhibition in nondiabetic progressive renal insufficiency: A controlled double-blind trial. Am J Kidney Dis. 1996;27(4):489-495. (Pubitemid 26106596)
37. Hoerger TJ, et al. A health policy model of CKD: 2. The cost-effectiveness of microalbuminuria screening. Am J Kidney Dis. 2010;55(3):463-473.